Melanoma
The company reported that its Barrett's esophagus risk assay saw volumes more than triple in Q3 2023 compared to the same period last year.
Following a recent leadership change, glycoproteomics firm InterVenn Biosciences is reevaluating its commercial strategy and direction.
Castle Biosciences Gains New York State Approval for Pittsburgh Laboratory
The company can now serve NY state patients from either of its two facilities, in addition to populations across other US states under its existing CLIA certifications.
DermTech to Cut 15 Percent of Workforce in Restructuring to Focus on Skin Cancer Test
The San Diego-based company said it will halt its pipeline programs in order to focus on growing volume and reimbursement for its noninvasive melanoma DNA test.
Liquid Biopsy Firms Eye Melanoma for Minimal Residual Disease Testing, Though Questions Remain
Premium
MRD assays show promise in immunotherapy response prediction with the potential to guide dose/treatment escalation with emerging adjuvant approaches.